Placental Transport of Immunoglobulins: A Clinical Review for Gastroenterologists Who Prescribe Therapeutic Monoclonal Antibodies to Women During Conception and Pregnancy

Kane, Sunanda V.; Acquah, Letitia A.
January 2009
American Journal of Gastroenterology;Jan2009, Vol. 104 Issue 1, p228
Academic Journal
The introduction of biologic therapy with therapeutic monoclonal antibodies to the treatment strategies of inflammatory bowel disease (IBD) has significantly changed the way clinicians practice. Antibodies are cleared differently than small molecules, and knowledge about the pharmacology and immunology of immunoglobulins is helpful when using these agents in women preconception and during pregnancy. The most commonly used antibody therapies in patients with IBD are IgG1 molecules, but others are under development. When treating patients who are pregnant or contemplating pregnancy, it is important to remember that immunoglobulin G (IgG) is the predominant means of fetal immunity and that it is transported across the placenta. This transport happens in a linear fashion as the pregnancy progresses, with the largest amount transferred in the third trimester. Preferential transport occurs for IgG1, followed by IgG4, and IgG3 with IgG2 being the least detected. Understanding the mechanism for immunoglobulin transfer will help to understand how to minimize risk of exposure of the fetus to the therapeutic monoclonal antibody both in utero and after delivery.


Related Articles

  • Pre-eclampsia is associated with the failure of melanoma cell adhesion molecule (MCAM/CD146) expression by intermediate trophoblast. Qin Liu; Xiyun Yan; Yang Li; Ying Zhang; Xingang Zhao; Yi Shen // Laboratory Investigation (00236837);Feb2004, Vol. 84 Issue 2, p221 

    The purpose of this study was to determine whether the expression of melanoma cell adhesion molecule (MCAM/CD146), like most other endothelial adhesion molecules, is reduced in the pregnancy disorder pre-eclampsia, and whether it is associated with the invasiveness of trophoblast. We used...

  • Keratin 19: Predicted Amino Acid Sequence and Broad Tissue Distribution Suggest it Evolved from Keratinocyte Keratins. Stasiak, Pauline C.; Purkis, Patricia E.; Leigh, Irene M.; Lane, E. Birgitte // Journal of Investigative Dermatology;May89, Vol. 92 Issue 5, p707 

    The type I keratin 19 is unusual in its tissue distribution in that under normal circumstances it does not seem to be restricted, as the other keratins are, to expression in either stratified or simple epithelia. In addition to the previously reported distribution of keratin 19 in human tissues,...

  • Monoclonal Immunoglobulin Deposition Disease: Light Chain and Light and Heavy Chain Deposition Diseases and Their Relation to Light Chain Amyloidosis. Buxbaum, Joel N.; Chuba, Joseph V.; Hellman, Gerard C.; Solomon, Alan; Gallo, Gloria R. // Annals of Internal Medicine;3/15/90, Vol. 112 Issue 6, p455 

    Provides information on monoclonal immunoglobulin deposition disease. Materials and methods used in the study; Clinical features of patients with light chain and heavy chain amyloidosis; Details of immunoglobulins in light and heavy chain deposition diseases.

  • Monoclonal antibodies in the clinic. Reichert, Janice M. // Nature Biotechnology;Sep2001, Vol. 19 Issue 9, p819 

    Presents a picture of the success of monoclonal antibodies (mAbs) in the clinic. Most suitable choice of mAb class to pursue as a therapeutic; Monoclonal revolution; Overview of monoclonal antibodies by design.

  • Editorial: Therapeutic Antibodies and Derivatives: From the Bench to the Clinic. Beck, A.; Wurch, T.; Corva�a, N. // Current Pharmaceutical Biotechnology;Dec2008, Vol. 9 Issue 6, p421 

    The article discusses various reports published within the issue including one on therapeutic monoclonal antibodies and another on human antibodies generated by phage-display.

  • immunoaffinity purification.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1160 

    A definition of the term "immunoaffinity purification," which refers to exposure to monoclonal antibodies so as to isolate analytes is presented.

  • To affinity and beyond. Moore, Pete; Clayton, Julie // Nature;12/11/2003, Vol. 426 Issue 6967, p725 

    Discusses uses of antibodies to researchers. Protection against infection; Changes in antibodies to meet researchers' demands; Business end of an antibody molecule; Human monoclonal antibody for the therapeutic use in humans.

  • Fc?RIIb engagement kills tumors. Hare, Peter // Nature Biotechnology;Oct2011, Vol. 29 Issue 10, p885 

    The article discusses research published in "Science" which demonstrated the antitumor activity of mutations in the Fc regions of CD40-binding monoclonal antibodies (mAbs) which increase the affinity of mAb for antigen-presenting cells (APC) Fcy receptor IIb.

  • Tailor-Made Monoclonal Antibodies. DePinho, Ronald A.; Feldman, Lori B.; Scharff, Matthew D. // Annals of Internal Medicine;Feb86, Vol. 104 Issue 2, p225 

    Examines the basic biology of antibody molecules and the genes that encode them and discusses how the knowledge can be applied to make more effective monoclonal antibodies. Structure and function of an antibody molecule; Diversity and heavy chain switching of antibodies; Production of antibodies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics